Business
The partnership will allow BMS to advance a T cell–based therapy that is only activated once in the vicinity of a tumor.
FEATURED STORIES
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The company has produced a varied pipeline focused on the development of precision pharmacological treatments for nine different programs.
Another drug Vounatsos heralded was zuranolone, which Biogen is developing with Sage Therapeutics for multiple forms of depression.
Moderna roared through 2021 on the strength of its COVID-19 vaccine and that momentum is continuing in 2022.
BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.
The collaboration covers several neurodevelopmental targets, including Rett syndrome, SYNGAP1 syndrome, and one other disease yet to be disclosed.
Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.
Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants Bayer access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
On Friday morning, AstraZeneca’s rare disease group Alexion and Switzerland-based Neurimmune entered into a collaboration and licensing agreement for NI006.